BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:VAY736 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of VAY736\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05639114-10731@assetmemo.bio
DTSTAMP:20261121T004037Z
DTSTART;VALUE=DATE:20270326
DTEND;VALUE=DATE:20270327
SUMMARY:VAY736: Phase 3 readout est. (NCT05639114)
DESCRIPTION:VAY736\, phase 3.\nStudy: Phase 3 Study to Evaluate Two Regimen
 s of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemi
 c Lupus Erythematosus (SIRIUS-SLE 1)\nEstimated primary completion: 26 Mar
 ch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/vay736#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05639114
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05624749-10731@assetmemo.bio
DTSTAMP:20261121T004037Z
DTSTART;VALUE=DATE:20270412
DTEND;VALUE=DATE:20270413
SUMMARY:VAY736: Phase 3 readout est. (NCT05624749)
DESCRIPTION:VAY736\, phase 3.\nStudy: Phase 3 Study to Evaluate Ianalumab o
 n Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythema
 tosus (SIRIUS-SLE 2)\nEstimated primary completion: 12 April 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/vay736#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05624749
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06470048-10731@assetmemo.bio
DTSTAMP:20261121T004037Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:VAY736: Phase 2 readout est. (NCT06470048)
DESCRIPTION:VAY736\, phase 2.\nStudy: A Clinical Study to Evaluate Ianaluma
 b in Participants With Diffuse Cutaneous Systemic Sclerosis\nEstimated pri
 mary completion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/vay736#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06470048
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05126277-10731@assetmemo.bio
DTSTAMP:20261121T004037Z
DTSTART;VALUE=DATE:20270921
DTEND;VALUE=DATE:20270922
SUMMARY:VAY736: Phase 3 readout est. (NCT05126277)
DESCRIPTION:VAY736\, phase 3.\nStudy: Safety\, Efficacy and Tolerability of
  Ianalumab Versus Placebo\, Combination With SoC Therapy\, in Participants
  With Active Lupus Nephritis\nEstimated primary completion: 21 September 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/vay736#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05126277
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07421167-10731@assetmemo.bio
DTSTAMP:20261121T004037Z
DTSTART;VALUE=DATE:20290118
DTEND;VALUE=DATE:20290119
SUMMARY:VAY736: Phase 2 readout est. (NCT07421167)
DESCRIPTION:VAY736\, phase 2.\nStudy: A Study to Assess the Tolerability of
  Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Ago
 nist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)\nE
 stimated primary completion: 18 January 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/vay736#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07421167
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621809-10731@assetmemo.bio
DTSTAMP:20261121T004037Z
DTSTART;VALUE=DATE:20290815
DTEND;VALUE=DATE:20290816
SUMMARY:VAY736: Phase 3 readout est. (NCT07621809)
DESCRIPTION:VAY736\, phase 3\, Sjögren's Disease.\nStudy: Two Arm\, Double
 -blind\, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus
  Placebo\, in Participants With Sjögren's Disease With High Symptom Burde
 n\nEstimated primary completion: 15 August 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/vay736#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07621809
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07660172-10731@assetmemo.bio
DTSTAMP:20261121T004037Z
DTSTART;VALUE=DATE:20330422
DTEND;VALUE=DATE:20330423
SUMMARY:VAY736: Phase 2 readout est. (NCT07660172)
DESCRIPTION:VAY736\, phase 2.\nStudy: A Study of Ianalumab in Addition to E
 ltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroi
 ds.\nEstimated primary completion: 22 April 2033. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/vay736#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07660172
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05985915-10731@assetmemo.bio
DTSTAMP:20261121T004037Z
DTSTART;VALUE=DATE:20330422
DTEND;VALUE=DATE:20330423
SUMMARY:VAY736: Phase 3 readout est. (NCT05985915)
DESCRIPTION:VAY736\, phase 3.\nStudy: A Randomized\, Double-blind 2-arm\, F
 ollowed by an Open-label 1-arm\, NEPTUNUS Extension Study to Assess the Lo
 ng-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrom
 e.\nEstimated primary completion: 22 April 2033. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/vay736#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05985915
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06133972-10731@assetmemo.bio
DTSTAMP:20261121T004037Z
DTSTART;VALUE=DATE:20340403
DTEND;VALUE=DATE:20340404
SUMMARY:VAY736: Phase 3 readout est. (NCT06133972)
DESCRIPTION:VAY736\, phase 3.\nStudy: Phase 3 Extension Study to Evaluate L
 ong-term Safety of Ianalumab in Participants With Systemic Lupus Erythemat
 osus (SIRIUS-SLE Extension).\nEstimated primary completion: 3 April 2034. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/vay736#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06133972
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06711887-10731@assetmemo.bio
DTSTAMP:20261121T004037Z
DTSTART;VALUE=DATE:20350801
DTEND;VALUE=DATE:20350802
SUMMARY:VAY736: Phase 3 readout est. (NCT06711887)
DESCRIPTION:VAY736\, phase 3.\nStudy: Phase III Extension Study of Efficacy
  and Safety of Ianalumab With or Without Study Treatment Withdrawal in Par
 ticipants With Lupus Nephritis (SIRIUS-LN Extension)\nEstimated primary co
 mpletion: 1 August 2035. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/vay736#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06711887
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
